摘要
目的评价肝动脉化疗栓塞术联合索拉非尼治疗晚期不可切除肝癌的疗效。方法 12例肝动脉化疗栓塞术联合索拉非尼治疗的晚期不可切除肝癌患者作为实验组,同时选出年龄段相同并只接受肝动脉化疗栓塞术的晚期不可切除肝癌患者42例作为对照组。比较两组的总有效率、临床获益率、中位无进展生存期(PFS)和中位总生存时间(OS)。结果两组总有效率分别为42%和38%,临床获益率分别为75%和71%,差异无统计学意义(P>0.05);PFS分别为8个月和5.1个月;OS分别为16个月和9.3个月。中位PFS和中位OS比较差异有统计学意义(P<0.05)。结论肝动脉化疗栓塞术联合索拉非尼治疗晚期不可切除肝癌与单纯使用肝动脉化疗栓塞术相比预期生存更长。
Objective To evaluate the curative effect of transhepatic arterial chemotherapy and embolization combined with sorafenib in the treatment of advanced unresectable liver cancer. Methods There were 12 patients with advanced unresectable liver cancer selected into the experimental group, and they received transhepatic arterial chemotherapy and embolization combined with sorafenib. Another 42 patients with advanced unresectable liver cancer in the same age were chosen as the control group, and they received transhepatic arterial chemotherapy and embolization only. The total effective rates, clinical benefit rates, median progression free survival（PFS） and media overall survival（OS） were compared between the two groups. Results The total effective rates were respectively 41% and 38% in the two groups, and the clinical benefit rates were 75% and 71%. The difference had no statistical significance（P〈0.05）. Median PFS were 8 months and 5.1 months, and median OS were 16 months and 9.3 months. The difference of median PFS and median OS had statistical significance（P〈0.05）. Conclusion Transhepatic arterial chemotherapy and embolization combined with sorafenib in the treatment of advanced unresectable liver cancer has longer expected survival than transhepatic arterial chemotherapy and embolization along in treatment.
出处
《中国实用医药》
2015年第6期21-22,共2页
China Practical Medicine
关键词
肝动脉化疗栓塞术
索拉非尼
肝癌
Transhepatic arterial chemotherapy and embolization
Sorafenib
Liver cancer
